LGL Group (NYSEAMERICAN:LGL) Share Price Crosses Above 200-Day Moving Average – Here’s Why

LGL Group, Inc. (The) (NYSEAMERICAN:LGL) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $6.50 and traded as high as $7.16. LGL Group shares last traded at $7.00, with a volume of 2,827 shares trading hands.

LGL Group Trading Down 0.1%

The firm has a market capitalization of $45.71 million, a PE ratio of 63.64 and a beta of 0.34. The business’s 50 day simple moving average is $7.15 and its two-hundred day simple moving average is $6.50.

LGL Group (NYSEAMERICAN:LGL) last announced its earnings results on Monday, March 30th. The industrial products company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.09). The company had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $9.10 million. LGL Group had a net margin of 16.50% and a return on equity of 1.66%. As a group, equities research analysts anticipate that LGL Group, Inc. will post 0.12 earnings per share for the current year.

Institutional Investors Weigh In On LGL Group

A hedge fund recently raised its stake in LGL Group stock. Osaic Holdings Inc. boosted its holdings in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) by 15.5% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 20,250 shares of the industrial products company’s stock after buying an additional 2,710 shares during the period. Osaic Holdings Inc. owned 0.38% of LGL Group worth $154,000 as of its most recent SEC filing. Institutional investors own 30.28% of the company’s stock.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.